Podcast appearances and mentions of christopher sweeney

PODCAST CROSSOVER!!! Talk Art and Homo Sapiens UNITE!!! A celebration of LGBTQI+ History Month 2021!Dear Listeners, something different and EXCLUSIVE for you. We have done a really fun collaboration with the brilliant podcast @HomoSapiens hosted by legendary actor @AlanCummingSnaps and TV/film director @ChrisSweeney. We’ve created a mash up episode! In this intimate 2 hour conversation, we discuss the art that inspired us in our teenage years, the story of Alan’s friendship with Madonna, art made during the 1980s AIDS epidemic and the giants of Queer Art like #DavidHockney, #AndyWarhol, #RobertMapplethorpe and #TomOfFinland plus we get all the intel on the next generation of trailblazing Queer artists like #CatherineOpie and #KehindeWiley. Plus, how does a Naan bread fit into #AlanCumming’s art collection??? THANK YOU ALAN & CHRIS! WE LOVE YOU!!The episode is split between our two feeds. So catch part 1 on Talk Art’s Podcast feed, and part 2 on the Homo Sapiens' Podcast feed.#TalkArtPodcast #HomoSapiensPodcast #LGBTQ #art #queerartLINK TO PART 2 at HOMO SAPIENS: https://linktr.ee/HomoSapiensPodcastFor images of all artworks discussed in this episode visit @TalkArt. Talk Art theme music by Jack Northover @JackNorthoverMusic courtesy of HowlTown.com We've just joined Twitter too @TalkArt. If you've enjoyed this episode PLEASE leave us your feedback and maybe 5 stars if we're worthy in the Apple Podcast store. For all requests, please email talkart@independenttalent.com See acast.com/privacy for privacy and opt-out information.

Featuring a discussion from Drs Daniel P Petrylak, Christopher Sweeney and Robert Dreicer, including the following topics: Role of Androgen Receptor-Targeted Therapies in Nonmetastatic Castration-Resistant Prostate Cancer — Dr Petrylak (0:00) Treatment of Polymetastatic Hormone-Sensitive Prostate Cancer — Dr Sweeney (31:35) Therapeutic Strategies for Metastatic Castration-Resistant Prostate Cancer — Dr Dreicer (1:14:51) CME information and select publications

The Castologists are here to wade through the oceans of offerings and fish out the best pods for your ear holes. This week Zane looks at inspirational stories with added Alan Cumming and Christopher Sweeney in Homo Sapiens. Liz gets historical with added Aussie flair in Bloody Classic. And Nick gets his NASA on with added Apollo mission intrigue with 13 Minutes To The Moon. Then it’s review time as always.Liz Recommends - Bloody ClassicBloody Classic is an Aussie podcast that shares stories from history, mythology and folklore. Each episode Liz & Mattie take turns telling a new story designed to teach the other a little something something, and see what sort of whacked out response comes out. Join them on your morning commute or on a lazy Sunday afternoon as they weave tales that will (hopefully) aid your next round of trivia. They promise not to take up too much of your time.Eps are usually about 20 mins, but they havent released since May. The curse of 2020 strikes again.For both: pick an ep that interests you.https://podcasts.apple.com/us/podcast/bloody-classic/id1265609037Nick Recommends - 13 Minutes to the MoonThe story of the first moon landing, told by the people who made it happen.For both: Pick a mission!https://podcasts.apple.com/us/podcast/13-minutes-to-the-moon/id1459657136Zane Recommends - Homo Sapienshttps://homosapienspodcast.com/Alan Cumming and Christopher Sweeney talk to inspirational people over tea and biscuits. Each week they'll bring you intelligent, informative, and fun conversations that represent the interests of LGBTQ+ people around the world.For Both: Pick one that appealshttps://podcasts.apple.com/gb/podcast/homo-sapiens/id1257514825 See acast.com/privacy for privacy and opt-out information.

Uniting as a community, as the body of Christ, we are the Anti-Virus destroying the true virus, which is evil. Now is the time for God's Children to Rise in actions to destroy the Beast!

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Robert Dreicer, Daniel P Petrylak, and Christopher Sweeney on the following topics: Introduction (00:00) M0 Castration-Resistant Prostate Cancer (PC) (1:11) Metastatic Hormone-Sensitive PC (20:48) Metastatic Castration-Resistant PC (35:39) ASCO Journal Club (56:10) CME information and select publications

A special audio program from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Robert Dreicer, Daniel P Petrylak, and Christopher Sweeney.

Join Caroline Wilson, Corrie Perkin and producer Jane Nield for their Good Local Tips for Ep 136. SHOW NOTESMidwife Cath's – tips for foggy glasses. Eurovision Song Contest: The Story of Fire Saga on NetflixThe Australian Movie collection on ABC iView. Huge range of classic films available for free HERE.Homo Sapians the podcast with Alan Cumming and Christopher Sweeney available HEREPears are the perfect fruit to bake with in winterLeisure pants – Vicki recommends Mela Purdie and Amanda recommends Abbi & Joseph. Corrie likes Cotton On.Listener Marika gave us a brilliant guide to Bendigo. Here’s all the GLT for a weekend. Arrive Friday afternoon in time for a pre-dinner drink next to the roaring log fire at Wine Bank On View before heading around the corner to sink into a green velvet seat at Ms Batterhams a new Bendigo restaurant in an old school building. Saturday morning, head to Harvest Food and Winefor Marsha’s incredible croissants.Jane recommends some therapeutic weaving if you’re trimming back vines in the garden. There’s plenty of videos on Youtube that teach you how, like the one HERE.SecondBite are a wonderful food rescue organisation. Hear Siomone and Ian Carson talk about their work on the Great Australian Lives podcast HERE. To support SecondBite head to www.secondbite.orgListener Max recommends Why Women Kill on SBS On demandFor videos and pics make sure you follow us on Instagram @DontShootPod.Like our Facebook page and hit 'Sign Up' to receive weekly updates HERE.Email the show via feedback@dontshootpod.com.au.Don't Shoot the Messenger is produced, engineered and edited by Jane Nield for Crocmedia.

Part 1 With Chris Sweeney from Right MealzJoin Thomas Ardavany & Suzanne Toro on JoyScore Live. We have special guests Chef Paul, Founder of Primal Alchemy and Christopher Sweeney. We will showcase the Primal Alchemy '2' Dudes and Food. We will share our passion for food, well being, sustainability, seasonal cuisine, nutrition and inspiring success stories.Chris Sweeney grew up in South Orange County and ended up in Long Beach to compete as a track and field athlete for The University of Long Beach. After college, he got into the business of Real Estate for about four years experiencing many difficult times during my efforts on becoming a successful relator.However, life took a turn and directed him to his destiny with fitness and food. People took notice to the way his body looked and how in shape he was. Then, he had a realtor from a previous office ask if he could cook for him. With no hesitation, he said “of course!”This is the seed that lead Chris to create RightMealz.www.rightmealz.com/suzannetoro.com/besimplyradio/ind…s-in-the-joyzone/www.klbp.org/

Part 2 with Primal Alchemy and Chef PaulJoin Thomas Ardavany & Suzanne Toro on Indie Creators in the JoyZone. We have special guests Chef Paul, Founder of Primal Alchemy and Christopher Sweeney. We will showcase the Primal Alchemy '2' Dudes and Food. We will share our passion for food, well being, sustainability, seasonal cuisine, nutrition and inspiring success stories.Chef PaulPrimal Alchemy is a Chef-driven catering company serving all of Southern California, specializing in cooking with organic, seasonal, locally sourced ingredients.With a thorough background in traditional culinary preparation, and a progressive approach that incorporates the increasingly popular Farm To-Table Philosophy, Primal Alchemy collaborates with local producers to provide a diverse array of food that is extremely fresh, simply seasoned, and prepared in the most straightforward manner.After graduating with honors from the California Culinary Academy in San Francisco, Chef Paul honed his cooking skills in some of the best kitchens in Southern California, including Water Grill, Patina, Pascals and Campanile. At Patina he executed large scale events like the Oscars, Emmys, SAG Awards gaining valuable experience in logistics as well as cooking.Primal Alchemy was created to share his passion for seasonal, sustainable, local cuisine. Primal, meaning, first or premiere and Alchemy, the transformation of something. Cooking is the first science of man...in other words, First Transformation.Chef Paul Buchanan participates in Kids in the Kitchen, Slow Food, Chefs Collaborative, American Institute of Wine and Food, guest chefs at several “Real Food” events throughout the year and has been featured in many cookbooks.primalalchemy.com/suzannetoro.com/besimplyradio/ind…s-in-the-joyzone/klpb.org

Adapted from the acclaimed novel NEITHER WOLF NOR DOG by Kent Nerburn the story follows a white author who gets sucked into the heart of contemporary Native American life in the sparse lands of the Dakota’s by a 95-year old Lakota elder and his side-kick. NEITHER WOLF NOR DOG takes audiences on a deeply moving road trip through contemporary Lakota life. Its humor is wry and pulls no punches, introducing deep characters and poignant vignettes that challenge the viewer to see the world differently. Neither Wolf Nor Dog was audience-financed, shot in 18-days in one of the US’s poorest region with an average crew of 2 and a 95-year-old Lakota Elder, David Bald Eagle, as the star. The Lakota actor, soldier, stuntman and musician, David Bald Eagle was left for dead during D-Day and Christopher Sweeney was awarded the Silver Star from the Gulf War. Yet it was the film’s other star, Yuchi-Muscogee Creek multi-disciplinary visual artist, poet, and actor, Richard Ray Whitman, who was never in the service, who spent the most days under fire during the 71-day occupation of Wounded Knee in 1973. Neither Wolf Nor Dog has become one of the widest released, truly self-distributed movies in years. Simpson flipped the Hollywood model upside-down by launching in small towns and it has the longest theatrical first-run of any movie in at least a decade: 131 weeks so far. Director / Producer / Writer / Editor / Cinematographer Steven Lewis Simpson joins us for a conversation on his determination to pursue own path of independent filmmaking, distribution, marketing and bringing seldom heard stories to a broader audience. About the filmmaker: At 18 Steven Lewis Simpson was Britain’s youngest fully qualified stockbroker and trader. At 22 he moved to Los Angeles to work for the legendary Roger Corman’s Concorde Pictures. It was there Simpson shot his first feature TIES. He shot his first documentary TIMOR TIMOR in West Timor, Indonesia, produced and co-edited the award-winning surreal fairy tale, FROG which was broadcast on Canal Plus and associate produced the comedy feature, RESURRECTING BILL. His epic feature documentary A THUNDER-BEING NATION about the Oglala Lakota of Pine Ridge Reservation was released in 2016. Made over 13 years it’s the most comprehensive documentary looking at the history and contemporary life of an Indian Reservation. He capped off the trio of Native American projects with a 13 episode US TV show THE HUB about arts, culture and entertainment within Indian Country. Through this work Steven has become a well-known advocate for Native American rights and a respected figure in Indian Country. Simpson’s latest feature is an adaptation of the acclaimed Lakota Country novel NEITHER WOLF NOR DOG is being released in 2019. He is currently in post-production on the feature documentary RETURN TO TIMOR, shot in West Timor, Indonesia. For more about the filmmaker go to: stevenlewissimpson.com For news, screenings and updates go to: neitherwolfnordogfilm.com

Welcome to the ASCO Daily News Podcast. I'm Dr. Richard Schilsky, senior vice president and chief medical officer of ASCO. I am pleased to be joined by Dr. Christopher Sweeney, a medical oncologist and professor of medicine at Harvard Medical School and Dana Farber Cancer Institute. He presented abstract LBA2 entitled overall survival results of a phase three randomized trial of standard of care therapy with or without enzalutamide for metastatic hormone sensitive prostate cancer, the ENZAMET trial, an ANZUP led international cooperative group trial. Dr. Sweeney, welcome to the podcast. Thank you for having me. So testosterone suppression and androgen receptor blockade, of course, have been the cornerstone of treatment for men with advanced prostate cancer for many, many years. This large trial of men with metastatic hormone sensitive prostate cancer demonstrated an overall survival advantage by substituting enzalutamide for older androgen receptor blockers. Tell us more about how the patients did on this treatment. Well, the first big line item to report is that men who got the drug enzalutamide, which, as you point out, is the more potent version of the way to block the androgen receptor than our old drugs, lived longer. In terms of relative risk, men had a 33% chance of being alive longer than men who got the older drugs. In terms of absolute numbers, 80% of men who got the early drug were alive at three years versus 72%. What's buried in all those numbers, though, is that there are different patient populations. Patients who have a higher burden disease, have a faster progression, and, unfortunately, a shorter survival than men who have a lower burden of disease. With our previous iteration of this type of a trial in men starting hormones, we showed that docetaxel benefited patients who had high volume disease very clearly. And we could also see enzalutamide works just as well with docetaxel in that patient group. On the other hand, men who had a low burden of disease, we didn't really see a benefit with chemotherapy docetaxel. But we did see a big benefit here in this study with using the hormone enzalutamide. So that now comes to the question, well, what about men who are treated with docetaxel? Did enzalutamide help them? And we actually had a group of patients in this study who we can pull out and analyze separately. And we can see that the enzalutamide delayed the time to progression when it was added to the docetaxel. But at this early analysis, we don't see any meaningful impact in survival. And that could well be because men who get the hormones and the docetaxel and then have the drugs, like enzalutamide, do just as well as getting all three drugs upfront, testosterone suppression, docetaxel, and the enzalutamide, do just as well as getting docetaxel, testosterone suppression, followed by enzalutamide. So it's a little bit of a parsing out of who the patients were and what treatments they get to work out how they actually fared. Tell us a little bit more about enzalutamide. This is a drug that's already FDA approved. It's already in use for later lines of therapy. How does it differ from the earlier group of androgen receptor blockers? Do you attribute all of the benefits seen in the enzalutamide group to the drug itself, or were there differences in patient populations perhaps from groups studied with the earlier generation of androgen receptor blockers? It seems like a pretty substantial improvement just by swapping out a newer version of an old drug. Yes, that's a very interesting observation. So the first notion is that the drug was tailored and designed by chemistry to be a much more potent version of the old drugs. So they're able to see the crystal structure of the androgen receptor and then do chemistry to say, how can we block that and shut that receptor down more efficiently? What is unique about the trial design, because we ran this as an academic study, is that we incorporated in a control arm, every patient had to have one of the older less potent drugs as a control to really show that the more potent drug did actually have all the benefits and conferred the benefits over the older drug. So it wasn't versus a non-active placebo. So it's very clear as a direct more potent versus less potent drug, we had a survival benefit. The other thing to note is that we had clues that this may work is because patients who have testosterone suppression and when their cancer progressed, they had an up regulation of the androgen receptor. So the cells say, help me, help me. I need more testosterone or testosterone like hormones to live. And it up regulates that receptor to survive. And it becomes a target that we can use. Whereas the older drugs would be able to bind to it. But sometimes, they actually became agonists. They turned the receptor on rather than turning it off. Where this drug has complete antagonistic turning the receptor off properties. So it's really quite a clear more potent drug versus less potent drug leading to the survival benefit across both patients with a poor risk, higher volume disease and a lower risk, lower volume disease. It's really interesting how understanding the structure of the androgen receptor and the chemistry of the drug really seems to have led to a very substantial improvement in patient outcomes. So this is a drug, as I mentioned earlier, that's already FDA approved, although in another line of therapy, but could potentially be substituted into routine clinical care immediately. Do you think the study results justify making that switch? It's a very important question. So another way to phrase what you just said there, Rich, is we're seeing advances in advanced stage disease. And my mantra is let's go forward by moving backwards into the earliest stage disease where the patients are starting the hormone not when they're progressing on the testosterone suppression. So when they're starting the hormones, we actually see a survival benefit when we give it upfront. That is a new indication. And so it will be up to the developer of the drug, which is both co-developed by a company called Pfizer and [INAUDIBLE], to present that to the FDA and see if it will get a label extension from the castration setting, resistance setting to the hormone sensitive setting. So that's a work in progress. Now the important item is to recognize that to be able to access the drug, there's going to have to think through the side effect profile. And there are some side effects with regard to it can cause a little bit more fatigue, a little bit more impairing concentration because of the way it works. And some patients can feel a little bit more frail. So some patients have these side effects, and there have to be dose modifications. So the risk and benefit profile has to be adjudicated. But by patients living longer and having their cancer controlled for longer, most patients do get a benefit. But the flip side is we also have to work out other alternatives. Docetaxel is an alternative for patients with high volume disease. Abiraterone is another drug that's approved in this setting, which is another different type of a hormone. And when we write for these drugs, we have to adjudicate how much the patient is going to have to pay. Some patients, they have a copay of $5. Other patients, a copay of about $2,500, because these drugs are very expensive. And if patients have no insurance, the cost is close to $9,000. So I think it is a very good option that will emerge. I suspect it will get approved. But when patients are counseled by their physicians on the options, they have to review the side effects, the benefits, as well as the financial access issues. Yeah, very important points to bring up. So it always comes down to risks, benefits, and costs, and how that translates into access. So just to wrap up, obviously, prostate cancer is a very common disease. As our population continues to age, I think we can foresee that it may become even more common in the population. What's on the horizon for prostate cancer research and treatment? This is a disease where there's been a considerable amount of progress has been made in recent years. But perhaps, there's going to be a growing medical need as the population continues to age. So where do you see the future in prostate cancer research? So the first thrust of work that I'm actively involved in and have engaged with collaborations around the globe to do more trials is to go even further back into the disease setting and augment the adjuvant therapy around the time of prostate radiation or prostate surgery to decrease the risk of relapse. So we have less patients who actually develop metastatic disease and die of the disease. So a lot of us are now getting very proactive in that setting. The other setting is profiling the tumors to work out which patients would be better treated with our current chemotherapy, be it the hormones, be it the combination, as well as develop new drugs that target new targets that are identified. So early identification and more aggressive proactive treatment to prevent relapses. And if patients do relapse, interrogate the tumors more to get more informative data on how best to treat the patient with which new drugs that emerge. So just along those lines actually, your comment prompted a thought. One of the other abstracts presented in the plenary session was about a PARP inhibitor for maintenance therapy in patients with pancreatic cancer, certainly a difficult disease to treat. There's been some preliminary evidence that PARP inhibitors may have activity in prostate cancer as well. Do you think that's going to be an emerging molecular target in prostate cancer? I definitely think it will be. And to some degree, it already is a player. What we need to do is being conducted are the proper rigorous trials to work out, which is the genomic profile that of the DNA damage repaired defects in the genes like the BRCA2 gene you're referring to, that actually do portend a potential response. So we see that the DNA damage genes, response genes that may portend a response to a PARP inhibitor are about 20%. But maybe half of those are truly the genes that really are the responders, that define the responders. And the question now is, of those particular genes that are refined, how many of those actually respond and how long? So we're seeing, I would say, responses of about 50% in that subgroup. So it is very much the notion of precision medicine, because it's the precise group of patients, which inherently is a small subset, but a subset that we can identify and potentially give a meaningful treatment with a reasonable side effect profile. So that data should emerge over the next 12 to 24 months, I think, based on the status of the trials. Great. Thanks so much for giving us that little glimpse into the future. So again, today, my guest has been Dr. Christopher Sweeney from Harvard Medical School and Dana Farber Cancer Institute. Chris, thanks so much for being on the podcast today.   It was my honor. And to our listeners, thank you for tuning into the ASCO Daily News Podcast. If you're enjoying the content, we encourage you to rate us and review us on Apple Podcasts

Just four games left now, and still the title is up for grabs. Just below Bayern and BVB, Leipzig are nearly nailed-on for third but the remaining European puzzle is very much in pieces on the kitchen table. Matt calls up Abel Meszaros to talk all this over, as well as - because Matt is a Hertha fan and Abel is Hungarian - juuuust a little more Pal Dardai. In the middle is a nice little interview with Christopher Sweeney, author of Mad Dog Gravesen: The Last of the Modern Footballing Mavericks. Produced by Aidan Rantoul.

Tom manages to talk to Christopher Sweeney author of the new biography "Mad Dog Gravesen" all about former blue Thomas Gravesen. Chris tells us all about his book, the personalities he spoke to about Tommy and what Tommy is up to now Make sure to Subscribe to The Toffee Blues Podcast and leave us a rate! To buy a copy of Christopher's book you can purchase here from Amazon: https://www.amazon.co.uk/Mad-Dog-Gravesen-Footballing-Mavericks/dp/1785314858

Tom manages to talk to Christopher Sweeney author of the new biography "Mad Dog Gravesen" all about former blue Thomas Gravesen. Chris tells us all about his book, the personalities he spoke to about Tommy and what Tommy is up to now Make sure to Subscribe to The Toffee Blues Podcast and leave us a rate! To buy a copy of Christopher's book you can purchase here from Amazon: https://www.amazon.co.uk/Mad-Dog-Gravesen-Footballing-Mavericks/dp/1785314858

Hello soccer fans! We are back with a full hour of MLS and CCL news and entertainment (Nick even works in a Robert Kraft joke amidst his usual puns). With so much going on around Major League Soccer, we dive right in: CJ Sapong was traded to Chicago and no one is impressed. Real Salt Lake signs USL player Portillo to add depth to their midfield, and FC Cincinnati introduces their new mascot - Gary the Lion - who is the soccer equivalent of a scary clown. Next, our hosts recap the 1st leg of the Concacaf Champions League. Toronto FC falls flat against Panamanian side Independiente for the second time, Atlanta gets upset by Herediano of Costa Rica, but Sporting Kansas City, Houston Dynamo, and Red Bulls New York all come away with wins. Nick still thinks RBNY will be the first MLS team to win the tournament, but Sporting KC may have the easiest path to the finals. Mike and Nick also continue their MLS 2019 Team Previews. In this episode, they break down the roster moves and potential for New England Revolution, New York City FC, Red Bulls New York, Philadelphia Union, and the Portland Timbers. These teams span from league cellar-dwellers to MLS Cup Contenders, but all have entertaining story lines to follow as the season gets underway. Finally, we want to put in a plug for new friend of the show Christopher Sweeney. This author recently released Mad Dog Gravesen: The Last of the Modern Footballing Mavericks, about the footballing spectacle that was Thomas Gravesen. Order online if you're a fan of European football or great soccer stories. Thanks for listening, and please join the conversation on twitter @SOPSoccer or on facebook @sonsofapitchsoccer. Stay tuned for our final team preview episode later this week, but in the meantime, enjoy all the soccer action!

This week Jorge and Mark recap the latest action and signings for the Vancouver Whitecaps, and look ahead to the final preseason matches against Tijuana and LAFC. In the second half of the show Mark is joined by author Christopher Sweeney to discuss his new book titled Mad Dog Gravesen: the Last of the Modern Footballing Mavericks. Footballer Thomas Gravesen rose to the pinnacle of football after a humble start in a small Danish town. By the time he retired early at the age of 32 Gravesen had nearly 70 caps for Denmark, played in the UEFA Champions League and blew up the Hamburg training pitch with dynamite. Chris tells us all about the life and times of Gravesen: the good, the bad, and the ugly, and why football is better with characters like Thomas. Buy the book on Amazon here. FEEDBACK: E-mail: fromthebackline@outlook.com Twitter: @FromTheBackline Facebook: From the Backline Podcast This podcast may not be reproduced in whole or in part without the express written consent of FTBL Media. © Copyright 2019 FTBL Media. All rights reserved.    

United suffered their first loss under Solskjaer, losing 0-2 to PSG, but then bounced right back with a 0-2 victory against Chelsea at Stamford Bridge! Spurs were magnificent against Dortmund and we're excited to see how they fare in the Champions League.  Also, we talk to journalist and author Christopher Sweeney! Chris has a new book about Thomas Gravesen out, called "Mad Dog Gravesen - The Last Of The Modern Footballing Mavericks". Chris talks to us about many of Thomas Gravesen's mad stories from his time at Everton and Real Madrid. It's a fun book about a mad character! You can buy the book on Amazon by clicking here!   And don't forget to join The Corner Flag FPL league by using this code: 452292-1350750 The Corner Flag is produced by Prashant Soni. You can give him a shoutout on Instagram and Twitter! Follow Mukesh on Instagram and Twitter! Follow Amogh on Instagram, Twitter and Facebook! And don't forget to rate us and write us a nice review!

Good grief there are a lot of guests in the podcupboard this week – Jo and James are joined by Will Young and Christopher Sweeney, the co-hosts of the brilliant "LGBTQ+ Woman's Hour" Homo Sapiens podcast, and an incredibly determined bit of air conditioning inside Will’s dressing room at the Piccadilly Theatre. They discuss Will’s starring role in the new production of Strictly Ballroom, the dangers of roller skates, and how to end up with an incredible successful podcast when you don’t listen to them. And the team discuss their IIJMS: is it just Will who doesn’t talk to his neighbours? Is it just James who’s reached a stage in life where he’s waiting for second marriages to come around? And is it just Chris who never takes photos anymore? This week's episode was recorded on May 24. It was edited by Kat Brown, with music by Martin Austwick. Join in the conversation using #isitjustmepodcast, email us your “is it just me?” thoughts on isitjustmepodcast@gmail.com, and find us onTwitter... @jo_elvin | @JamesConradW12 | @katbrown | @willyoung | @mrchrissweeney and on Instagram... @jo_elvin | @JamesConradW12 | @katbrown82 | @willyoungofficial | @mr_chris_sweeney And thank you for listening! We'd love it if you rated and reviewed us on iTunes as it helps other people to find our show. See acast.com/privacy for privacy and opt-out information.

This year is 100th Anniversary of the battle at Vimy Ridge. Libby talks with Christopher Sweeney, the President of the Vimy Ridge Foundation, about what it was, and why it was such an important event in Canadian history. And

This year is 100th Anniversary of the battle at Vimy Ridge. Libby talks with Christopher Sweeney, the President of the Vimy Ridge Foundation, about what it was, and why it was such an important event in Canadian history. And – The Ontario government is taking steps to protect your savings from unscrupulous advisors and it's the result of a CARP initiative. Libby is joined by CARP's VP of Advocacy Wanda Morris to talk about it.

A diagnosis of Cancer often comes with lots of questions. And naturally, and these days people turn to the internet for answers. But it turns out hopping online for this kind of info can do more harm than good. Lacey Horta from the Canadian Cancer Society joins Libby to talk about why.Plus , we're coming up to April 9th, which has been declared as Vimy Ridge Day. A day to commemorate the deaths and casualties of members of the Canadian Corps who fought in the Battle of Vimy Ridge during the First World War. This year marks the 99th anniversary of that historic battle. Libby is joined by Christopher Sweeney, chair of the Vimy Foundation to talk about why it's important to preserve and promote this legacy.

A diagnosis of Cancer often comes with lots of questions. And naturally, and these days people turn to the internet for answers. But it turns out hopping online for this kind of info can do more harm than good. Lacey Horta from the Canadian Cancer Society joins Libby to talk about why.Plus , we're coming up to April 9th, which has been declared as Vimy Ridge Day. A day to commemorate the deaths and casualties of members of the Canadian Corps who fought in the Battle of Vimy Ridge during the First World War. This year marks the 99th anniversary of that historic battle. Libby is joined by Christopher Sweeney, chair of the Vimy Foundation to talk about why it's important to preserve and promote this legacy.

Porter Gulch Review editor Christopher Sweeney talks about the newest issue and its release party this Friday the 13th from 6-9pm at Cabrillo College Campus in Aptos, CA.

Interview — video. Christopher Sweeney. In his thesis, Foreign Flag Vessels in the Great Lakes and the Risk to Homeland Security, USCG Lieutenant Commander Christopher Sweeney strives to bring an awareness of the problem... The post Thesis Series: Foreign Flag Vessels in the Great Lakes and the Risk to Homeland Security appeared first on CHDS/Ed.